Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria may hold key to better nutrition for cancer patients

NCT ID NCT07260617

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the bacteria in the gut and mouth relate to nutrition in 150 adults with digestive cancer starting chemotherapy. Researchers will collect stool and saliva samples, along with questionnaires and tests, before and after the first chemo cycle. The goal is to find bacterial patterns linked to malnutrition, which could lead to new ways to support patients' nutrition during treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify gut bacteria as targets to improve nutrition and quality of life for cancer patients on chemotherapy.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear links, and any potential therapies would need years of additional testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated with chemotherapy in digestive oncology

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria \* : * Adult patient * Patient with digestive cancer, including: * Borderline or locally advanced pancreatic adenocarcinoma * Metastatic pancreatic adenocarcinoma without symptomatic peritoneal carcinomatosis * metastatic colon/rectal cancer without symptomatic peritoneal carcinomatosis * Patients with an indication for chemotherapy (induction treatment or treatment of metastatic disease) * Patients able to eat orally at the time of inclusion in the study * Patients with a performance status (PS) score ≤2 * Patients who agree to provide stool and saliva samples * Patients who have given their written informed consent * Patients affiliated with the French social security system * Exclusion Criteria : * Pregnant or breastfeeding women * Patients who have received antibiotics within 3 weeks prior to the first chemotherapy treatment (excluding antibiotic prophylaxis administered in the context of surgery or endoscopy). * Individuals receiving psychiatric care that may interfere with their ability to respond to questionnaires (in the investigator's opinion) * Persons deprived of their liberty or subject to legal protection measures (guardianship, curatorship) * Patients participating in another interventional study with medication * Patients who have undergone chemotherapy for another malignant tumor in the last 12 months. * Patients with another synchronous malignant tumor, with the exception of adequately treated carcinoma in situ of the cervix or squamous cell carcinoma of the skin, or limited basal cell or squamous cell skin cancer. This cancer must then be adequately controlled. * Patients with symptomatic brain and/or meningeal metastases. * Patients who have undergone digestive resection (excluding appendectomy or cholecystectomy \>12 months ago). * Patients with symptomatic peritoneal carcinomatosis prior to the start of chemotherapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Borderline or locally advanced pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm digestive system cancer digestive system neoplasm Malnutrition pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digestive cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Croix Rousse Hospital Hepatology and Gastroenterology Department

    Lyon, 69004, France

  • Edouard Herriot Hospital - medical oncology department

    Lyon, 69003, France

  • Lyon Sud Hospital - Hepatology and Gastroenterology Department

    Lyon, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.